Phase III Study: Tiotropium Effective In Symptomatic Asthma Patients
Tuesday, May 21, 2013 - 09:20
in Health & Medicine
Tiotropium delivered by the Respimat(R) Soft Mist(TM) Inhaler (SMI) increases time to first severe exacerbation and first episode of asthma worsening across a broad spectrum of patients who remain symptomatic despite at least inhaled corticosteroids (ICS) / long-acting beta2-agonists (LABA) therapy. The results are from pre-planned subgroup analyses of data from the PrimoTinA-asthma(TM) Phase III studies being presented for the first time today at the 2013 American Thoracic Society (ATS) congress in Philadelphia, Pennsylvania. read more